Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure. We were founded in April 2019 by a team of leading pharmaceutical and biotechnology executives and academics with deep ca...
DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure. We were founded in April 2019 by a team of leading pharmaceutical and biotechnology executives and academics with deep cardiology and gene therapy expertise. Our company is headquartered in Pfäffikon, Switzerland, with additional presence in London, England and Boston, Massachusetts.

List your booth number for exhibitions, ask us